El interés en corto de Scholar Rock Holding da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Scholar Rock Holding. Los datos de interés en corto se actualizan cada dos semanas.

Scholar Rock Holding (NASDAQ:SRRK) Bolsa, Informe de interés en corto

SCHOLAR ROCK HOLDING CORP

Scholar Rock Holding

Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding Corp

Craig-Hallum analyst Chase Knickerbocker maintains Indivior (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) with a Buy and raises the price target from $15 to $22.

News

Price Target

Analyst Ratings

INDV

Craig-Hallum Maintains Buy on Indivior, Raises Price Target to $22

Mercurity Fintech Holding Inc. (the "Company," "we," "us," "our company," or "MFH") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>), a digital fintech group, today announced that it has officially joined the Russell 2000&#xAE; Index, effective after the U.S. market close on June 27. The inclusion follows MFH's addition to the preliminary reconstitution list announced on May 23, 2025, as part of FTSE Russell's annual index review process.
MFH has also been included in the broader Russell 3000&#xAE; Index, marking a significant milestone for the Company as it gains access to a broader base of institutional investors who track these widely followed benchmarks.

Mercurity Fintech Joins Russell 2000 And Russell 3000 Indexes

CBAT

CBAK Energy Forms Partnership With Anker Innovations To Establish A Battery Cell Manufacturing Facility In Malaysia; Establishes Long-Term Cooperation Framework With Orders Valued At ~$357M

IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders, today unveiled the key achievements and advancements that defined Fiscal Year 2025, ended March 31, 2025. This past year has been nothing short of transformative, marked by significant clinical progress, strategic expansion, and growing recognition for our pioneering approach to Alzheimer's disease.

Biotech

General

IGC Pharma Highlights Fiscal Year 2025 With Clinical Progress And Alzheimer's Drug Development Advances

Shigeru Ishiba, the Prime Minister of Japan, is contemplating a proposal from President&nbsp;Donald Trump&nbsp;to purchase American oil to address the trade imbalance between the two nations.
What Happened: Ishiba acknowledged the suggestion but emphasized the need for a more detailed assessment. He pointed out that while the U.S. is the largest oil producer, factors such as price and oil type need to be considered, in an interview with&nbsp;<a href="https://asia.nikkei.com/Editor-s-Picks/Interview/Ishiba-weighs-up-Trump-s-suggestion-that-Japan-buy-US-oil?ref=biztoc.com">Nikkei</a>&nbsp;on Monday.
The Japanese PM stated, &#8220;It is a possibility that requires further, more detailed consideration.&#8221;
&#8220;Oil is different from natural gas,&#8221; Ishiba said, adding, &#8220;You cannot just say, &#8216;Yes, we&#8217;re&nbsp;ready to buy a lot&nbsp;of oil from the U.S.'&#8221; This comes amid renewed concerns over Japan&#8217;s energy security following the recent Israel-Iran conflict.
Trump has been urging countries like Japan and South Korea to invest&nbsp;in natural gas fields in&nbsp;Alaska, a move Japan is considering to diversify its energy sources. &nbsp;The suggestion holds particular importance as Japan currently relies on the Middle East for&nbsp;90% of its oil supply and recent tensions in the Strait of Hormuz have sparked concerns about energy security.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/sports/25/06/46159984/mark-cuban-raises-employee-wages-after-learning-of-government-aid-dependence" target="_blank" rel="noreferrer noopener">Mark Cuban Raises Employee Wages After Learning Of Government Aid Dependence</a>
Why It Matters: Japan&#8217;s consideration of Trump&#8217;s proposal comes at a critical time. The country has been engaged in trade talks with the U.S., with the looming threat of a 25% automotive tariff. Japan&#8217;s chief trade negotiator,&nbsp;Ryosei Akazawa, has previously&nbsp;<a href="https://www.benzinga.com/markets/tech/25/06/46109160/japans-top-trade-negotiator-calls-trumps-25-auto-tariffs-unacceptable-amid-ongoing-talks">expressed</a>&nbsp;Japan&#8217;s refusal to accept these tariffs, further complicating the trade negotiations.
In an interview with Fox News on Sunday, Trump said the U.S. has a large trade deficit with Japan and suggested that Japan could help reduce it by buying more American oil and other goods. 
Meanwhile, Trump&#8217;s recent announcement of his intention to set new&nbsp;<a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46163141/trump-says-hell-skip-trade-deals-set-global-tariffs-with-a-letter-pay-a-25-tariff-or-20-or-40-or-50">tariff rates</a>&nbsp;unilaterally for various trading partners through letters adds another layer of uncertainty to the trade negotiations. This move could potentially impact Japan&#8217;s trade relations with the U.S. and other countries.
Japan&#8217;s decision on the U.S. oil proposal could have significant implications for the ongoing trade talks and the broader trade relationship between the two countries.
On a year-to-date basis, shares of Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) climbed 1.93%, while Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) fell 1.99%, as per <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>. 
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46051740/nearly-40-years-ago-donald-trump-blamed-this-country-for-his-tariff-push-and-its-not-china-id-make-our-allies-pay-their-fair-share">Nearly 40 Years Ago, Donald Trump Blamed This Country For His Tariff Push — And It&#8217;s Not China: &#8216;I&#8217;d Make Our Allies Pay Their Fair Share&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Japan Weighs 'Possibility' Of US Oil Purchase After Trump's Proposal: 'Requires...More Detailed Consideration,' Says PM Ishiba

Citigroup analyst Patrick Cunningham upgrades Linde (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>) from Neutral to Buy and raises the price target from $500 to $535.

Upgrades

Citigroup Upgrades Linde to Buy, Raises Price Target to $535

WANG &amp; LEE GROUP, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) ("Wang &amp; Lee" or the "Company"), a Hong Kong-based construction prime and subcontractor engaging in the installation of Electrical &amp; Mechanical Systems, today announced that as previously announced on May 7, 2025, the Company received a letter (the "Notification Letter") from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market, LLC ("Nasdaq") on May 6, 2025, notifying the Company that, based upon the closing bid price of the Company's ordinary shares for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Requirement"), which matter serves as a basis for delisting the Company's securities from Nasdaq. Additionally, the Company's securities had a closing bid of $0.10 or less for the last ten consecutive trading days, and accordingly, is subject to the provisions under Listing Rule 5810(c)(3)(A)(iii). This serves as an additional basis for delisting.
On June 25, 2025, the Company received an additional Notification Letter notifying the Company that the Staff has determined to delist the Company's securities pursuant to their discretionary authority under Listing Rule 5101. The Staff's determination was based on public interest concerns primarily in relation to the Company's June 9, 2025 issuance of convertible notes.
The Company has filed a notice of appeal and requested a hearing before a Nasdaq Listing Qualifications Panel to review the Staff's determination. The appeal will stay delisting of the Company's securities pending the Panel's decision.

WLGS

Wang & Lee Received Letter Of Nasdaq Delisting, Over Bid Price And Convertible Note Concerns; Appeals To Stay Decision Pending Hearing

NESR

NESR Joins Russell 2000 And Russell 3000 Indexes

Amber International Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBR#NASDAQ">AMBR</a>) ("Amber International", or the "Company"), a leading provider of institutional crypto financial services &amp; solutions and operating under the brand name "Amber Premium", today announced that it has successfully entered into subscription agreements for a private placement totaling $25.5 million. This strategic financing is backed by a group of distinguished investors, including Mile Green, Harvest Capital, Pantera Capital, Choco Up, and other leading investors from Asia, signaling strong confidence in Amber International's growth trajectory and market leadership.
The proceeds will be used to accelerate Amber International's expansion in key institutional crypto services across the U.S. and Southeast Asia, with a focus on enhancing its crypto reserve strategy, asset tokenization in areas of stablecoins and real-world assets (RWAs), as well as innovative AI-AgentFi initiatives, all subject to prevailing laws and regulations in relevant jurisdictions.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Offerings

Markets

AMBR

Amber International Secures $25.5M In Private Placement Backed By Pantera, Harvest Capital, And Others To Expand Crypto Services And Advance AI, Stablecoin, And Real-World Assets Strategies

Management

Harte Hanks Appoints David Fisher As President

VOXR

Vox Royalty Added To Russell 2000 And 3000 Index

Ostin Technology Group Co., Ltd. ("the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>), a leading supplier of display modules and polarizers based in China today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of an aggregate of 41,666,667 of the Company's Class A ordinary share, par value $0.001 per share (the "Shares") (or pre-funded warrants in lieu thereof) at a purchase price of $0.12 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.001 per share.
The aggregate gross proceeds to the Company of this offering are expected to be approximately $5 million. The transaction is expected to close on or about July 1, 2025, subject to the satisfaction of customary closing conditions.
Univest Securities, LLC is acting as the sole placement agent.

Ostin Technology Announces $5M Registered Direct Offering Of 41.7M Shares At $0.12 Each With Pre-Funded Warrants Option

As recently <a href="https://jaguarhealth.gcs-web.com/news-releases/news-release-details/proof-concept-results-show-crofelemer-reduced-total-parenteral">announced</a>, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome patient by up to 12.5%
The first two patients in this IIT were taken off crofelemer after 12 weeks of treatment for a period intended to last 30 days, per the study protocol, but were promptly placed back on daily crofelemer treatment because their symptoms worsened
Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's intestinal failure products, resulting in non-dilutive funding for Jaguar
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 30, 2025 / <a href="https://pr.report/bxg0">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/bxg2">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/bxg3">Napo Therapeutics</a> today announced that initial proof-of-concept results show that a novel liquid formulation of crofelemer reduced the required total parenteral nutrition (TPN) and supplementary intravenous fluids in a third intestinal failure patient. This is the second pediatric patient with intestinal failure due to the orphan disease short bowel syndrome (SBS-IF) who was treated with crofelemer. To date, three patients with intestinal failure due to SBS-IF or microvillus inclusion disease (MVID) have been treated with crofelemer in this exploratory, single-arm open label non-randomized IIT in Abu Dhabi.

JAGX

Jaguar Health's Napo Announces That Initial Proof-Of-Concept Results From Ongoing IIT Show Liquid Formulation Of Crofelemer Reduced Required TPN And Supplementary Intravenous Fluids In Third Intestinal Failure Patient

Strategists from JPMorgan have voiced concerns that the much-awaited Federal Reserve interest-rate cuts might not be as beneficial for stocks as investors hope.
What Happened:  JPMorgan strategists, led by Mislav Matejka, observed a growing anticipation of interest rate cuts from the Fed. However, they caution that the reasons behind these cuts might not bode well for stocks, according to a <a href="https://www.marketwatch.com/story/the-wrong-kind-of-fed-rate-cuts-are-coming-says-jpmorgan-what-that-means-for-stocks-bonds-and-the-dollar-2d31c6e1?mod=home_ln">MarketWatch</a> report.
The strategists outlined three possible scenarios for the rate cuts. The first is a situation where the Fed cuts rates due to a clear weakening of economic activity. The second scenario, referred to as the &#8220;Goldilocks&#8221; case, features robust growth alongside mild inflation, with no strain on consumer purchasing power. The third scenario involves rate cuts despite emerging inflation, possibly due to pressure from the U.S. administration for lower rates.
The strategists predict a blend of the first and third scenarios, where activity is slowing but inflation is on the rise. They caution that investors might be disappointed if this outlook materializes. They also noted that the dollar typically weakens into the cuts and continues to fall afterwards, while bond yields move lower.
&#8220;Historically, whenever the Fed resumed its easing cycle following a pause, the dollar tended to weaken and continue declining, while bond yields also dropped,&#8221; noted JPMorgan strategists. They now anticipate the U.S. dollar hitting &#8220;new lows in most scenarios&#8221; and expect U.S. bond yields to fall as well.
They also predict that emerging market stocks will perform well when the Fed eases, and are reiterating their overweight on the region. 
SEE ALSO: <a href="https://benzinga.com/news/politics/25/06/46162859/trump-threatens-to-cut-federal-funding-for-nyc-if-zohran-mamdani-doesnt-do-the-right-thing-as-future-mayor-if-he-does-get-in-im-going-to-be-president" target="_blank" rel="noreferrer noopener">Trump Threatens To Cut Federal Funding For NYC If Zohran Mamdani Doesn&#8217;t Do The &#8216;Right Thing&#8217; As Future Mayor: &#8216;If He Does Get In, I'm Going To Be President&#8230;&#8217; &#8211; Benzinga</a>
Why It Matters: The Fed&#8217;s decision to cut interest rates is contingent on various factors. Fed Chair Jerome Powell recently stated that while inflation has <a href="https://www.benzinga.com/markets/economic-data/25/06/46077396/powell-interest-rates-trump-inflation-tariffs">cooled </a>from its 2022 peak, it remains &#8220;somewhat elevated,&#8221; and the central bank is not ready to adjust interest rates yet. However, a &#8220;significant majority&#8221; of committee members expect to cut rates later this year.
One of the factors influencing the Fed&#8217;s decision is inflation data. Funsdtrat&#8217;s Tom Lee <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46088808/tom-lee-on-why-feds-holding-back-while-europe-eases-aggressively-thats-the-upside-opportunity-into-year-end">explained </a>that the European Central Bank&#8217;s decision to cut interest rates is linked to how it calculates core inflation—excluding housing costs. This differs from the U.S., where housing plays a significant role in inflation data. If the U.S. used Europe&#8217;s approach, its core CPI would appear lower than Europe&#8217;s, potentially justifying rate cuts.
Furthermore, the Fed&#8217;s decision on interest rates could be influenced by the next&nbsp;<a href="https://www.benzinga.com/news/25/06/46115346/trump-powell-fed-chairman-odds-dollar">Federal Reserve chair</a>. President&nbsp;Donald Trump&#8216;s shortlist for the next Fed chair is heating up, fueling bets on deep rate cuts, pressuring the dollar, and reigniting concerns over the Fed&#8217;s independence.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/markets/economic-data/25/06/46165307/us-credit-rating-would-fall-if-trumps-big-beautiful-bill-is-approved-says-thomas-massie-heres-what-it-means-for-americans" target="_blank" rel="noreferrer noopener">US Credit Rating Would Fall If Trump&amp;#39;s Big Beautiful Bill Is Approved, Says Thomas Massie: Here&amp;#39;s What It Means For Americans</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Fed Rate Cuts May Not Be A Win For Stocks, Warns JPMorgan — Expects Dollar And Bond Yields To Fall

Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced a historic milestone: the first participant has been dosed with CMND-100, its proprietary MEAI-based oral drug candidate, in its Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD). This marks the first time a patient has received Clearmind's innovative treatment in a clinical setting, a critical step toward the development of a potential new therapy for millions affected by AUD worldwide.
The dosing follows the Company's announcement on June 5, 2025, of the enrollment of the first participant in the trial, which is being conducted at leading clinical sites, including Yale School of Medicine's Department of Psychiatry and Johns Hopkins University School of Medicine in the United States as well as Tel Aviv Sourasky Medical Center (Ichilov) and Hadassah-University Medical Center in Jerusalem. The Phase I/IIa trial is designed to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also assessing its preliminary efficacy in reducing alcohol cravings and consumption in patients with AUD.

CMND

Clearmind Doses First Patient In Phase I/IIa Trial Of Psychedelic-Based CMND-100 For Alcohol Use Disorder

Stephens &amp; Co. analyst Matt Olney reiterates Guaranty Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNTY#NYSE">GNTY</a>) with a Overweight and maintains $47 price target.

Reiteration

GNTY

Stephens & Co. Reiterates Overweight on Guaranty Bancshares, Maintains $47 Price Target

&nbsp;Zynex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>), an innovative medical technology company specializing in noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of&nbsp;Steven Dyson&nbsp;as Chief Executive Officer. His employment will begin on August 18, 2025.
Thomas Sandgaard, Founder of Zynex and Chairman of the Board since the company's inception in 1996, will remain actively involved as Chairman and Chair of the Board's Technology Committee.

ZYXI

Zynex Announces Steven Dyson As New CEO, Effective  August 18, 2025

B of A Securities analyst Jason Gerberry downgrades ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) from Neutral to Underperform and lowers the price target from $3 to $1.

Downgrades

PROK

B of A Securities Downgrades ProKidney to Underperform, Lowers Price Target to $1

Jaguar Health And Napo therapeutics Announce Initial Proof-Of-Concept Results Showing Liquid Formulation Of Crofelemer Reduced Total Parenteral Nutrition In Third Intestinal Failure Orphan Disease Patient

KANZHUN LIMITED ("BOSS Zhipin" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZ#NASDAQ">BZ</a>, HKEX: 2076))), a leading online recruitment platform in China, today announced the pricing of its share offer (the "Share Offer") of an aggregate of 34,500,000 Class A ordinary shares of the Company, including 4,500,000 Class A ordinary shares offered pursuant to the Company's full exercise of the offer size adjustment option. The Share Offer is comprised of a Hong Kong public offering (the "Hong Kong Public Offering"), and an international offering (the "International Offering").
The final offer price for both the Hong Kong Public Offering and the International Offering (the "Offer Price") has been set as HK$66.00 per share. Based on the ratio of two Class A ordinary shares per Nasdaq-listed American depositary share ("ADS") and an exchange rate of HK$7.8499 to US$1.00, the Offer Price translates to approximately US$16.82 per ADS. The final offer price has been set by the Company out of sincerity, and the Company would like to express gratitude to its investors for their participation in the share offer.
Subject to approval from the Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange"), the Class A ordinary shares of the Company are expected to begin dealing on the Main Board of the Hong Kong Stock Exchange on Friday, July 4, 2025. The Share Offer is expected to close on the same day, subject to customary closing conditions.

KANZHUN LIMITED Prices ~$280.3M Public Offering Of 34.5M Class A Ordinary Shares At ~$16.82 Per ADS

Press Releases

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

Scholar Rock to Present at the Jefferies Global Healthcare Conference

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

Comments

Scholar Rock Holding

Interés en corto

Scholar Rock Holding (NASDAQ:SRRK) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL